A Phase 1 interventional study of TB006 and Placebo in Covid19, sponsored by TrueBinding, Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-18.
Sponsored by TrueBinding, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
TB006, a monoclonal antibody, is an anti-inflammatory and anti-fibrotic agent that reduces the severity of underlying diseases in COVID-19 patients. The primary objective of TB006 treatment is to decrease the potential acute severe deterioration in outpatient COVID-19 patients with underlying diseases, such as diabetes, hypertension, and cancer. TB006 has been developed to treat the ambulatory patients with diagnosed mild to moderate COVID-19 who are considered at low risk for severe disease or hospitalization.
TB006, a monoclonal antibody, is an anti-inflammatory and anti-fibrotic agent that reduces the severity of underlying diseases in COVID-19 patients. The primary objective of TB006 treatment is to decrease the potential acute severe deterioration in outpatient COVID-19 patients with underlying diseases, such as diabetes, hypertension, and cancer. TB006 has been developed to treat the ambulatory patients with diagnosed mild to moderate COVID-19 who are considered at low risk for severe disease or hospitalization.
In the single ascending dose study, the dosages of 5 mg/kg \~ 50 mg/kg will be investigated in patients with mild to moderate COVID-19, and will be administered to patients over 60 minutes after dilution in 0.9% Sodium Chloride Injection, USP (normal saline) to a final volume of 250 mL. The primary objective of the SAD study is to evaluate the safety and tolerability of single ascending doses of TB006 vs placebo administered via i.v. infusion in outpatient patients with mild-to-moderate COVID-19 and to determine the dose recommended for Phase Ib study.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →TrueBinding, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with mild to moderate COVID-19 experiencing any of the following symptoms:
Adequate organ function at screening as evidenced by:
Exclusion Criteria:
Clinical signs indicative of Severe or Critical Illness Severity
Respiratory failure defined based on resource utilization requiring at least one of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the SAD study, subjects will receive a single dose of TB006 (at the dosage level of 10 \~ 50 mg/kg) administered via i.v. infusion for 60 mins. In addition, a sentinel cohort of 5 mg/kg will be open for enrollment and double-blinded randomization first, with 2 patients randomized to active/TB006 arm, to assess preliminary safety and tolerability of study drug, and to determine cohort expansion and dose escalation. Upon the completion of sentinel cohort and all subjects are safe and well tolerate study treatment, regular dose escalation will start.
Drug: TB006
During the SAD study, subjects will receive a single dose of the placebo administered via i.v. infusion for 60 mins. In addition, the corresponding sentinel placebo group will include 1 patient to placebo arm. Upon the completion of sentinel cohort and all subjects are safe and well tolerate study treatment, regular dose escalation will start.
Other: Placebo
TB006 monoclonal antibody
Placebo i.v. infusion
Treatment emergent adverse events
Evaluated as per DAIDS v2.1
Time frame: Baseline to Day 85
Pharmacokinetic parameters of TB006: AUC(0-last)
- Area under the plasma concentration curve over time (hr\*µg/mL)
Time frame: Day 1 to Day 85
Pharmacokinetic parameters of TB006: Cmax
- Maximum concentration of TB006 (µg/mL)
Time frame: Day 1 to Day 85
Pharmacokinetic parameters of TB006: Tmax
- The amount of time that TB006 is present at the maximum concentration (hours)
Time frame: Day 1 to Day 85
Pharmacokinetic parameters of TB006: T1/2
- Half life of TB006 (hours)
Time frame: Day 1 to Day 85
Immunogenicity
- Anti-drug antibodies (ADA)
Time frame: Day 1 to Day 85
Preliminary Efficacy: Viral shedding change
Change from baseline in viral shedding from Day 1 to Day 28, as measured by RT-qPCR
Time frame: Day 1 to Day 28
Preliminary Efficacy: Viral shedding change at each visit
Change from baseline in viral shedding at each visit through Day 28, as measured by RT-qPCR
Time frame: Baseline to Day 28
Preliminary Efficacy: Time to viral shedding clearance
Measure the time to viral shedding clearance
Time frame: Baseline to Day 85
Preliminary Efficacy: Proportion of treated patients with ≥ 1 COVID-19 related medically-attended visit through Day 28
Proportion of treated patients with ≥ 1 COVID-19 related medically-attended visit through Day 28
Time frame: Baseline to Day 28
Preliminary Efficacy: Total number of COVID-19 related medically-attended visits
Number of COVID-19 related medically-attended visits during study
Time frame: Baseline to Day 28
Preliminary Efficacy: Proportion of treated patients admitted to a hospital due to COVID-19
Proportion of patients admitted to a hospital by Day 28
Time frame: Baseline to Day 28
Preliminary Efficacy: Time to sustained clinical recovery from baseline
Time to sustained clinical recovery from baseline to end of follow-up visits
Time frame: Baseline to Day 85
Preliminary Efficacy: Clinical improvement from baseline at each visit through Day 28 (in patients with or without underlying comorbidities
Measured by change in score according to the World Health Organization (WHO) ordinal scale, ranging from 0 (uninfected) to 8 (dead)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: Troponins
Change in cardiac biomarkers (ng/mL)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: N-terminal pro B-type natriuretic peptide (NT-proBNP)
Change in cardiac biomarkers (pg/mL)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: Creatine kinase-MB (CK-MB)
Change in cardiac biomarkers (ng/mL)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: Change in neutrophil-lymphocyte ratio (NLR)
Monitor potential inflammation activity
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: IL-6
- Change in cytokine measurement (pg/mL)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: IL-2
- Change in cytokine measurement (pg/mL)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: IL-7
- Change in cytokine measurement (pg/mL)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: IL-8
- Change in cytokine measurement (pg/mL)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: IL-1β
- Change in cytokine measurement (pg/mL)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: IFNgamma
- Change in cytokine measurement (pg/mL)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: TNFα
- Change in cytokine measurement (pg/mL)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: IL-10
- Change in cytokine measurement (pg/mL)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: MIP-1α/β
- Change in cytokine measurement (pg/mL)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: C-reactive protein (CRP)
- Change in serum and plasma biomarkers (mg/L)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: Ferritin
- Change in serum and plasma biomarkers (mg/L)
Time frame: Baseline to Day 28
Pharmacodynamics biomarkers: D-dimer
- Change in serum and plasma biomarkers (mg/L)
Time frame: Baseline to Day 28
Virology
- Change in viral sequencing, resistance, infectivity using RT-qPCR
Time frame: Baseline to Day 85
Patient Report Outcomes (PRO): Sponsor developed patient self-report COVID-19 symptom survey (PSRSS-C19)
- Change from baseline to Day 28 and safety follow-up visit in score ranging from 0 (none) to 3 (severe)
Time frame: Baseline to Day 85
Patient Report Outcomes (PRO): Patient Global Impression of Severity (PGI-S) survey
- Change from baseline to Day 28 and safety follow-up visit in score ranging from 0 (non) to 4 (very severe)
Time frame: Baseline to Day 85
Patient Report Outcomes (PRO): Patient Global Impression of Change (PGI-C) survey
- Change from baseline to Day 28 and safety follow-up visit in score ranging from 0 (much better) and 4 (much worse)
Time frame: Baseline to Day 85
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Sep 2021, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TB006
TrueBinding, Inc.